Login to Your Account

Financings Roundup

Verastem's $32M Series B to Fund Cancer Stem Cell Work

By Jennifer Boggs

Friday, July 15, 2011
Founded only last year to develop cancer drugs that work by attacking cancer stem cells, Verastem Inc. already has closed its second round on funding, bringing in $32 million in a Series B.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription